Edwards Lifesciences (NYSE:EW) VP Sells $237,907.12 in Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Annette Bruls sold 2,644 shares of the stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the transaction, the vice president owned 17,984 shares in the company, valued at approximately $1,618,200.32. This trade represents a 12.82% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock opened at $90.19 on Monday. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $96.29. The firm has a fifty day simple moving average of $89.54 and a 200-day simple moving average of $85.08. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $51.93 billion, a price-to-earnings ratio of 51.83, a PEG ratio of 2.37 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. The firm had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business’s revenue was up 13.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, sell-side analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have issued reports on EW. Evercore restated an “outperform” rating and issued a $100.00 price target on shares of Edwards Lifesciences in a research report on Monday, July 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Wall Street Zen downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Leerink Partners upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $87.00 to $101.00 in a research note on Friday, July 24th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. Seventeen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $100.27.

Institutional Investors Weigh In On Edwards Lifesciences

Hedge funds have recently made changes to their positions in the company. California State Teachers Retirement System boosted its position in Edwards Lifesciences by 9,187.8% in the second quarter. California State Teachers Retirement System now owns 80,962,062 shares of the medical research company’s stock valued at $7,323,828,000 after buying an additional 80,090,362 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of Edwards Lifesciences during the second quarter worth approximately $5,318,092,000. Bank of New York Mellon Corp bought a new position in shares of Edwards Lifesciences in the second quarter valued at approximately $1,274,082,000. Norges Bank bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $803,686,000. Finally, Bank of America Corp DE acquired a new position in shares of Edwards Lifesciences in the 2nd quarter worth approximately $605,397,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.